Candid Therapeutics

Subsidiary of UCB (UCBJY)

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1
BCMA x CD3Multispecific antibody
Systemic Lupus Erythematosus
Phase 1
CD20 x CD3Biologic (subtype unspecified)
Rheumatoid Arthritis
Phase 1
Undisclosed / early pipelineBiologic (subtype unspecified)
Rheumatoid Arthritis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.